Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer

Exibir registro simples

dc.contributor.author Leite, Daniela B. [UNIFESP]
dc.contributor.author Junqueira, Michele G. [UNIFESP]
dc.contributor.author Carvalho, Cristina V. de [UNIFESP]
dc.contributor.author Massad-Costa, Ana M. [UNIFESP]
dc.contributor.author Gongalues, Wagner J. [UNIFESP]
dc.contributor.author Nicolau, Sergio M. [UNIFESP]
dc.contributor.author Lopes, Luiz A. E. [UNIFESP]
dc.contributor.author Baracat, Edmundo C. [UNIFESP]
dc.contributor.author Silva, Ismael D. C. G. da [UNIFESP]
dc.date.accessioned 2016-01-24T13:51:31Z
dc.date.available 2016-01-24T13:51:31Z
dc.date.issued 2008-07-01
dc.identifier http://dx.doi.org/10.1016/j.steroids.2008.02.005
dc.identifier.citation Steroids. New York: Elsevier B.V., v. 73, n. 6, p. 676-680, 2008.
dc.identifier.issn 0039-128X
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/30774
dc.description.abstract The present case-control study evaluates the role of the progesterone receptor (PR) polymorphism known as PROGINS as a risk factor for ovarian cancer development and investigates the association between these genetic variants and clinical/pathologic variables of ovarian cancer. PROGINS polymorphism was examined, by polymerase chain reaction, in a total of 80 patients with ovarian cancer and 282 control subjects. the frequencies of PROGINS polymorphism T1/T1, T1/T2, and T2/T2 were 71.3, 15.0 and 13.8% in ovarian cancer patients and 78.37, 21.63 and 0% in controls, respectively the chi(2)-test showed a higher incidence of the T2/T2 genotype (P=0.001) in the ovarian cancer group. in addition, women carrying a mutated allele (T2) showed approximately 2.2 times higher risk of ovarian cancer development as compared to women who have a variant allele (odds ratio (OR) = 2.2; 95% CI = 1.80-3.54). Regarding the clinical and pathologic findings observed within the cancer group, there was a significant correlation between PROGINS polymorphism and patients with a familial history (chi(2) = 6.776; P = 0.009; Fischer exact test, P = 0.01). in this regard, patients with familial antecedents have a 4.7 times higher likelihood to have at least one risk allele (T2) as compared with patients without familial antecedents (OR = 4.69; 95% CI = 1.38-15.87). No correlations were observed among the other variables. These data suggest that the PROGINS polymorphism T2/T2 genotype might be associated with an increased risk of ovarian cancer. (C) 2008 Elsevier Inc. All rights reserved. en
dc.format.extent 676-680
dc.language.iso eng
dc.publisher Elsevier B.V.
dc.relation.ispartof Steroids
dc.rights Acesso restrito
dc.subject ovarian cancer en
dc.subject polymorphism en
dc.subject PROGINS en
dc.title Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer en
dc.type Artigo
dc.rights.license http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliation Universidade Federal de São Paulo UNIFESP EPM, Mol Gynecol Lab, Dept Gynecol, BR-04039032 São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo UNIFESP EPM, Mol Gynecol Lab, Dept Gynecol, BR-04039032 São Paulo, Brazil
dc.identifier.doi 10.1016/j.steroids.2008.02.005
dc.description.source Web of Science
dc.identifier.wos WOS:000255817100013



Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Exibir registro simples

Buscar


Navegar

Minha conta